Subarachnoid Haemorrhage (SAH) is a medical emergency with potentially devastating
outcomes. It is without doubt that over the past decades, there has been a radical change in the approach towards patients with SAH, both in terms of the surgical as well as of the pharmacological
treatments offered. The present review aims to outline the principal data regarding the best practice
in the pharmacotherapy of SAH, as well as to sum up the emerging evidence from the latest clinical
trials. To date, nimodipine is the only evidence-based treatment of vasospasm. However, extensive
research is currently underway to identify novel substances with magnesium sulphate, cilostazol,
clazosentan and fasudil, demonstrating promising results. Antifibrinolytic therapy could help reduce
mortality, and anticoagulants, in spite of their associated hazards, could actually reduce the incidence of delayed cerebral ischemia. The effectiveness of triple-H therapy has been challenged, yet
evidence on the optimal regimen is still pending. Statins may benefit some patients by reducing the
incidence of vasospasm and delayed ischemic events. As several clinical trials are underway, it is
expected that in the years to come, more therapeutic options will be added to the attending physician’s armamentarium.